الفهرس 
Aim of the workOnly 14 pages are availabe for public view
 |  | from | 132 |  |  |
| | | from | 132 | | |
Abstract
The purpose of the study is to evaluate the safety and efficacy of intravitreal ranibizmab versus bevacizumab in treatment of macular edema due to central or branch retinal vein occlusion.
We retrospectively compared the examination findings before and 3, 6 and 12 months after intravitreal ranibizmab or bevacizumab.
The study showed that: the mean baseline visual acuity, central foveal thickness and retinal volume were significantly reduced in both treatment groups. There was no significant difference between the two drugs. The mean number of injections of ranibizumab was 8 injections versus 5.3 injections in the bavacizumab group. No systemic or ocular adverse effects were observed in both treatment groups.
In conclusion, both intravitreal bevacizumab and ranibizumab are effective and safe in treatment of macular edema associated with branch or central vein occlusion, with significant higher number of injections in the ranibizumab group.